<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128058</url>
  </required_header>
  <id_info>
    <org_study_id>B7981045</org_study_id>
    <nct_id>NCT05128058</nct_id>
  </id_info>
  <brief_title>A Target Occupancy Study With Ritlecitinib.</brief_title>
  <official_title>AN OPEN LABEL, PHASE 1, TWO-ARM STUDY TO ASSESS TARGET OCCUPANCY AND FUNCTIONAL INHIBITION OF JAK3 AND TEC KINASES BY SINGLE DOSES OF RITLECITINIB IN HEALTHY ADULT PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, open label, two-arm study to assess target occupancy and functional&#xD;
      inhibition of JAK3 and TEC kinases by Ritlecitinib in healthy adult participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2021</start_date>
  <completion_date type="Anticipated">January 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in Target Occupancy (TO)</measure>
    <time_frame>Predose, 1 hr, 4 hr, 8 hr, 24 hr, and 48 hr post dose</time_frame>
    <description>Percent Change from Baseline in TO for Janus Kinase 3 (JAK3) and Tyrosine kinase Expressed in hepatocellular Carcinoma (TEC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Ritlecitinib</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax will be observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Ritlecitinib</measure>
    <time_frame>Day 1</time_frame>
    <description>Tmax will be observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at 48 hours post-dose (Clast) of Ritlecitinib</measure>
    <time_frame>48 hours post dose</time_frame>
    <description>Clast will be observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average plasma concentration from time 0 to 24 hrs (Cav) of Ritlecitinib</measure>
    <time_frame>Predose, 1 hr, 2 hr, 4 hr, 8 hr, and 24 hr post dose</time_frame>
    <description>Calculated as area under the concentration time curve over the dosing frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to 24 hours (AUC24) of Ritlecitinib</measure>
    <time_frame>Predose, 1 hr, 2 hr, 4 hr, 8 hr, 24 hr, and 48 hr post dose</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to 24 hours (dosing frequency)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of Ritlecitinib</measure>
    <time_frame>Predose, 1 hr, 2 hr, 4 hr, 8 hr, 24 hr, and 48 hr post dose</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (Clast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)</measure>
    <time_frame>Baseline (Day 0) up to 28 days after last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Laboratory Tests Results</measure>
    <time_frame>Baseline through study completion, approximately 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Categorical Vital Signs Data</measure>
    <time_frame>Baseline through study completion, approximately 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events by Severity</measure>
    <time_frame>Baseline up to 28 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with 50 mg Ritlecitinib on Day 1 and followed up till Day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with 200 mg Ritlecitinib on Day 1 and followed up till Day 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritlecitinib 50 mg</intervention_name>
    <description>50 mg single dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>PF-06651600</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritlecitinib 200 mg</intervention_name>
    <description>200 mg single dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>PF-06651600</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants are eligible to be included in the study only if all the following criteria&#xD;
        apply:&#xD;
&#xD;
          -  Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
          -  Male and female participants who are overtly healthy as determined by medical&#xD;
             evaluation including medical history, physical examination including BP and pulse rate&#xD;
             measurement, 12-lead ECG, or clinical and laboratory tests.&#xD;
&#xD;
          -  BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or&#xD;
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies at the time of dosing).&#xD;
&#xD;
          -  Infection with hepatitis B or hepatitis C viruses&#xD;
&#xD;
          -  Have evidence of untreated or inadequately treated active or latent Mycobacterium TB&#xD;
             infection&#xD;
&#xD;
          -  Known active or history of recurrent bacterial, viral, fungal, mycobacterial or other&#xD;
             infections.&#xD;
&#xD;
          -  Have received only one of the 2 required doses of COVID-19 vaccine.&#xD;
&#xD;
          -  Participants have a known present or a history of malignancy other than a successfully&#xD;
             treated or excised non metastatic basal cell or squamous cell cancer of the skin or&#xD;
             cervical carcinoma in situ.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7981045</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

